Entasis Therapeutics Holdings Inc (ETTX) Forecast, Price Target & Analyst Ratings

NASDAQ:ETTX • US2936141033

Current stock price

2.19
-0.01 (-0.45%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Entasis Therapeutics Holdings Inc (ETTX).

Forecast Snapshot

Consensus Price Target

Price Target
$2.04
-6.85% Downside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Aug 9, 2022
Period
Q2 / 2022
EPS Estimate
-$0.30
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
47.50%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$2.04
Upside
-6.85%
From current price of $2.19 to mean target of $2.04, Based on 8 analyst forecasts
Low
$2.02
Median
$2.04
High
$2.10

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for ETTX. The average price target is 2.04 null. This implies a price decrease of -6.85% is expected in the next year compared to the current price of 2.19.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ETTX Current Analyst RatingETTX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4

Analyst Ratings History

ETTX Historical Analyst RatingsETTX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
47.50%
ETTX was analyzed by 8 analysts. The buy percentage consensus is at 48. So analysts seem to be rather neutral about ETTX.
In the previous month the buy percentage consensus was at a similar level.
ETTX was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2022-05-06Cantor FitzgeraldDowngrade Overweight -> Neutral
2022-03-08WedbushDowngrade Outperform -> Neutral
2022-03-04HC Wainwright & Co.Downgrade Buy -> Neutral
2021-10-20BMO CapitalMaintains Outperform
2021-10-19HC Wainwright & Co.Maintains Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Aug 9, 2022
Period
Q2 / 2022
EPS Estimate
-$0.30
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-3.17%
Number of Analysts
5

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

ETTX is expected to report earnings on 8/9/2022. The consensus EPS estimate for the next earnings is -0.3 null and the consensus revenue estimate is 0 null.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2022 - 2026

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
ETTX revenue by date.ETTX revenue by date.
5M7M
40.00%		335.141K
-100.00%		7.994M32.963M
312.36%		80.791M
145.10%		201.978M
150.00%
EBITDA
YoY % growth
ETTX ebitda by date.ETTX ebitda by date.
-31.15M
-64.64%		-38.05M
-22.15%		-46.8M
-23.00%		-55.139M
-15.58%		-44.438M
3.46%		-36.529M
30.05%		N/AN/AN/AN/A
EBIT
YoY % growth
ETTX ebit by date.ETTX ebit by date.
-31.34M
-64.08%		-38.21M
-21.92%		-46.94M
-22.85%		-55.881M
-15.53%		-54.042M
3.52%		-64.344M
-22.98%		-62.269M
3.23%		-36.11M
42.01%		-43.409M
-20.21%		-53.227M
-22.62%
Operating Margin
ETTX operating margin by date.ETTX operating margin by date.
N/A-764.20%-670.57%-16,673.94%N/AN/A-778.97%-109.55%-53.73%-26.35%
EPS
YoY % growth
ETTX eps by date.ETTX eps by date.
N/AN/A-3.34
23.43%		-2.44
27.25%		-1.13
55.14%		-1.22
-11.98%		-1.17
3.90%		-0.64
45.65%		-0.78
-22.33%		-0.97
-24.78%

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 22 Q3 / 22 Q4 / 22
EPS
Q2Q % growth		-0.30
-3.17%		-0.31
-17.69%		-0.29
-15.60%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/A
EBIT
Q2Q % growth		-14.801M
-11.28%		-16.442M
-20.90%		-16.83M
-32.11%

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ETTX Yearly Revenue VS EstimatesETTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2023 2024 2025 2026 50M 100M 150M 200M
ETTX Yearly EPS VS EstimatesETTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
12.27%
EPS Next 5 Year
2.06%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

Entasis Therapeutics Holdings Inc / ETTX Forecast FAQ

What is the average price target for Entasis Therapeutics Holdings Inc (ETTX) stock?

8 analysts have analysed ETTX and the average price target is 2.04 null. This implies a price decrease of -6.85% is expected in the next year compared to the current price of 2.19.

Can you provide the upcoming earnings date for Entasis Therapeutics Holdings Inc?

Entasis Therapeutics Holdings Inc (ETTX) will report earnings on 2022-08-09.

What are the consensus estimates for ETTX stock next earnings?

The consensus EPS estimate for the next earnings of Entasis Therapeutics Holdings Inc (ETTX) is -0.3 null and the consensus revenue estimate is 0 null.

Can you provide the consensus rating for Entasis Therapeutics Holdings Inc stock?

The consensus rating for Entasis Therapeutics Holdings Inc (ETTX) is 47.5 / 100 . This indicates that analysts generally have a neutral outlook on the stock.